REFRACTORY PRIMARY-CUTANEOUS LARGE B-CELL LYMPHOMA (LEG-TYPE)

Clinical trials for REFRACTORY PRIMARY-CUTANEOUS LARGE B-CELL LYMPHOMA (LEG-TYPE) explained in plain language.

Never miss a new study

Get alerted when new REFRACTORY PRIMARY-CUTANEOUS LARGE B-CELL LYMPHOMA (LEG-TYPE) trials appear

Sign up with your email to follow new studies for REFRACTORY PRIMARY-CUTANEOUS LARGE B-CELL LYMPHOMA (LEG-TYPE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

New hope for rare leg lymphoma: lenalidomide shows promise in relapsed patients

Disease control Completed

This study tested the drug lenalidomide in 19 people with a rare type of skin lymphoma (leg-type) that returned or did not respond to initial chemotherapy plus rituximab. The goal was to see if lenalidomide could shrink tumors and control the disease. Results will help decide if …

Matched conditions: REFRACTORY PRIMARY-CUTANEOUS LARGE B-CELL LYMPHOMA (LEG-TYPE)

Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control

Last updated Jun 15, 2026 19:03 UTC

REFRACTORY PRIMARY-CUTANEOUS LARGE B-CELL LYMPHOMA (LEG-TYPE)

Get alerted when new REFRACTORY PRIMARY-CUTANEOUS LARGE B-CELL LYMPHOMA (LEG-TYPE) trials appear

New hope for rare leg lymphoma: lenalidomide shows promise in relapsed patients